I-Mab (IMAB)
1.04
-0.03 (-2.80%)
At close: Jan 14, 2025, 3:59 PM
1.03
-0.96%
After-hours Jan 14, 2025, 04:50 PM EST
undefined% (undefined)
| Bid | 0.98 |
| Market Cap | 80.10M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.04 |
| Volume | 258,898 |
| Avg. Volume (20D) | 488,049 |
| Open | 1.09 |
| Previous Close | 1.07 |
| Day's Range | 1.00 - 1.09 |
| 52-Week Range | 0.84 - 2.08 |
| Beta | undefined |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Pha...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 17, 2020
Employees 34
Stock Exchange NASDAQ
Ticker Symbol IMAB
Website https://www.i-mabbiopharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 669.23% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
+11.97%
I-Mab shares are trading higher. The stock may be ...
Unlock content with
Pro Subscription
